Plexium is the premier, next-generation targeted protein degradation company seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon IMiDs.

Plexium is replacing the complex infrastructure around drug discovery with an ultra-high-throughput microfluidic platform while reducing assay complexity and supercharging chemical diversity.

Plexium was founded in 2018 by Kandaswamy (Swamy) Vijayan. The company is headquartered in San Diego, California.


Plexium's platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation.


Plexium's screening platform, named DELPhe for DNA-Encoded Library (DEL) phenotypic (Phe) screening, utilizes droplet and microwell confinement to miniaturize cell-based assays that yield high content readouts at very low cost and very high throughput.


Plexium has entered into a strategic collaboration with Amgen to discover and develop new therapies for cancer and others serious diseases and is supported by high quality investors.


Plexium is backed by BVF Partners, TCG X, Softbank Vision Fund 2, RA Capital Management, The Column Group, DCVC Bio, Pivotal bioVenture Partners, Lux Capital, M Ventures, CRV, and others. The company raised $102M in a new round on Feb 23, 2022. This brings Plexium's total funding to $165M to date.



  • Year founded: 2018
  • Funding Info: $165M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: San Diego
  • State: California
  • Country: United States
Related businesses